If you are:
FDB Contraindicated or Not Recommended: FDA C BEFORE 30WKS;PREMATURE CLOSURE OF DUCTUS ARTERIOSUS;EARLY MISCARRIAGE RISK
Only When Necessary: INSUFFICIENT HUMAN DATA; ANIMAL DATA SUGGEST DEVELOPMENTAL TOXICITY
Precaution: INSUFFICIENT DATA AVAILABLE; LOW LEVELS FOUND IN BREASTMILK
Precaution: LOW LEVELS EXCRETED; MFR SUGGESTS DELAYING NURSING FOR 12 HOURS AFTER DOSE
An adult over 60:
management or monitoring precaution: Hepatic-Elderly patients are more likely to have decreased hepatic function thus decreasing drug clearance. Cardiovascular-Hypertensive effects may be more pronounced in the elderly and increase the risk for cardiovascular events in those with cardiovascular disease. A cardiovascular evaluation is recommended in those with CV risk factors, Avoid use of the drug in any patient with a cerebrovascular syndrome.
management or monitoring precaution: Gastrointestinal-Risk for ulceration or serious GI bleed; highest with history of PUD or GI bleed. Renal-Risk for exacerbation of CKD. Cardiovascular-May exacerbate pre-existing hypertension or CHF. Risk of cardiovascular thrombotic events, including MI and stroke. This risk may occur early in treatment and increases with duration of use. Risk for reinfarction with minimal NSAID use post-MI. Contraindicated with CABG. Hepatic-Elevated hepatic transaminases may occur with chronic use.
Giving sumatriptan-naproxen tablet to a child under 12:
Severe Precaution: Efficacy not established over placebo for treatment of migraine. Adverse event risk similar to adults including visual loss and stroke.
management or monitoring precaution: Safety and efficacy not established in children age less than 2 years.